Aurigene doses first volunteer under Phase 1 INDUS trial of AUR-101.
M2 PHARMA-July 12, 2018-Aurigene doses first volunteer under Phase 1 INDUS trial of AUR-101
(C)2018 M2 COMMUNICATIONS
Biotechnology company Aurigene reported on Wednesday the start of dosing of healthy volunteers with AUR-101 under its Phase 1 INDUS trial for the treatment of IL17-driven immunological conditions, including psoriasis.
AUR-101 is a selective, potent inverse agonist of the receptor RoR?t, designed as an oral agent for the treatment of IL17-driven immunological conditions, including psoriasis. AUR-101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients and also very significant reduction in ear swelling and histopathology scores in two separate pre-clinical psoriasis models.
The company added the study is designed to evaluate the safety signals, pharmacodynamic modulation and recommended dosage for Phase 2 studies (RP2D).
According to the company, it expects the data from the INDUS study to be available by December 2018.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 12, 2018|
|Previous Article:||RedDress passes US FDA's 510(k) clearance for RD1 system for wound management.|
|Next Article:||AcelRx Pharmaceuticals proposes public offering of common stock.|